3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
242
Lung Neoplasms
59
Neoplasms
57
Head and Neck Neoplasms
57
Stomach Neoplasms
56
Squamous Cell Carcinoma of Head and Neck
48
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Neoplasm Metastasis
40
Small Cell Lung Carcinoma
38
Urinary Bladder Neoplasms
28
Uterine Cervical Neoplasms
26
Esophageal Neoplasms
25
Colorectal Neoplasms
24
Cholangiocarcinoma
24
Biliary Tract Neoplasms
24
Carcinoma
23
Ovarian Neoplasms
21
Carcinoma, Transitional Cell
18
Carcinoma, Squamous Cell
17
Recurrence
16
Esophageal Squamous Cell Carcinoma
16
Melanoma
13
Breast Neoplasms
13
Non-Squamous Non-Small Cell Lung Cancer
12
Mesothelioma, Malignant
12
Mesothelioma
12
Nasopharyngeal Carcinoma
11
Endometrial Neoplasms
11
Adenocarcinoma
11
Gallbladder Neoplasms
10
Interventions
darolutamide
2
pembrolizumab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Male Urogenital Diseases
×
Cisplatin
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled